AgomAb Therapeutics NVAGMB +0.85%14 Shareholder Yield % is 0.02% as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,297 Biotechnology companies, AgomAb Therapeutics NV ranks better than 64.69% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, AgomAb Therapeutics NV's Shareholder Yield % was 0.02%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
AgomAb Therapeutics NV Shareholder Yield % Related Terms
AgomAb Therapeutics NV Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for AgomAb Therapeutics NV's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AGMB vs DNA, ACRS, RLMD: Shareholder Yield % Comparison
For the Biotechnology subindustry, AgomAb Therapeutics NV's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AgomAb Therapeutics NV Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where AgomAb Therapeutics NV's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
AgomAb Therapeutics NV (AGMB) has a Shareholder Yield % of 0.02% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on AgomAb Therapeutics NV and its competitors. According to the industry distribution chart, AgomAb Therapeutics NV ranks #458 out of 1297 companies in the Biotechnology industry, placing it in the top 35.3%.
Is AgomAb Therapeutics NV's Shareholder Yield % too high?
AgomAb Therapeutics NV's current Shareholder Yield % is 0.02%. Based on the distribution chart, AgomAb Therapeutics NV ranks #458 out of 1297 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Shareholder Yield % compare to DNA and ACRS?
According to the Biotechnology industry distribution chart, AgomAb Therapeutics NV ranks #458 out of 1297 companies for Shareholder Yield %. This puts AgomAb Therapeutics NV in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Shareholder Yield % is 0.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Shareholder Yield % of 0.02%. The current Shareholder Yield % is 0.02%. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Shareholder Yield % is 0.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score
Get the complete analysis for AGMB
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGMB has been successfully added to your 